|Calculated MW||This protein is fused with polyhistidine tag at the C-terminus, has a calculated MW of 26.1 kDa. The predicted N-terminus is Phe 29. DTT-reduced Protein migrates as 45-60 kDa due to glycosylation.|
|Other Names||B7-H4, VTCN1, B7S1, B7h.5|
|Results||Measured by its ability to inhibit anti-CD3 antibody induced IL-2 secretion in human T lymphocytes. The ED50 for this effect is typically 0.75 - 3 µg/ml.|
|Application Notes||Centrifuge the vial prior to opening. Reconstitute in sterile PBS, pH 7.4 to a concentration of 50 µg/ml. Do not vortex. This solution can be stored at 2-8°C for up to 1 month. For extended storage, it is recommended to store at -20°C.|
|Storage||-20°C; Lyophilized from 0.22 µm filtered solution in PBS, pH 7.4. Generally 5-8% Mannitol or trehalose is added as a protectant before lyophilization.|
email@example.com, and receive a free "I Love Antibodies" mug.
Provided below are standard protocols that you may find useful for product applications.
V-set domain-containing T-cell activation inhibitor 1 (VTCN1) is also known as Immune costimulatory protein B7-H4, Protein B7S1, T-cell costimulatory molecule B7x, B7H4, which belongs to the immunoglobulin superfamily and BTN/MOG family. VTCN1 contains two Ig-like V-type (immunoglobulin-like) domains. The expression of VTCN1 is up-regulated by IL6 and IL10 and is inhibited by GM-CSF and IL4 on antigen-presenting cells (APCs). VTCN1 / B7-H4 negatively regulates T-cell-mediated immune response by inhibiting T-cell activation, proliferation, cytokine production and development of cytotoxicity. VTCN1 involved in promoting epithelial cell transformation.
Sica G.L.,et al.Immunity 18:849-861(2003).
Zang X.,et al.Proc. Natl. Acad. Sci. U.S.A. 100:10388-10392(2003).
Sun Y.,et al.Lung Cancer 53:143-151(2006).
Mao Y.,et al.Submitted (OCT-2003) to the EMBL/GenBank/DDBJ databases.
Clark H.F.,et al.Genome Res. 13:2265-2270(2003).
If you have any additional inquiries please email technical services at firstname.lastname@example.org.